Mixed connective tissue disease: State of the art on clinical practice guidelines

B. Chaigne, Scirè Carlo Alberto, Talarico Rosaria, Alexander Tobias, Amoura Zahir, Avcin Tadej, Beretta Lorenzo, Doria Andrea, Guffroy Aurelien, Guimarães Vera, Hachulla Éric, Krieg Thomas, Launay David, Lepri Gemma, Moinzadeh Pia, Müller Ladner Ulf, Rednic Simona, Rodrigues Ana, Sander W. Tas, R. F. Van VollenhovenVieira Ana, Bombardieri Stefano, Fonseca João Eurico, Galetti Ilaria, Schneider Matthias, Smith Vanessa, Cutolo Maurizio, Mosca Marta, Fischer Betz Rebecca

Research output: Contribution to journalReview articlepeer-review


© 2018 Author(s) (or their employer(s)). Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematous in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle. In this narrative review, we summarise the results of a systematic literature research which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines (CPGs) or recommendations. Since no specific CPGs on MCTD were found, other CPGs developed for other CTDs were taken into consideration in order to discuss what can be applied to MCTD even if designed for other diseases. Three major objectives were proposed for the future development of CPGs: MCTD diagnosis (diagnostic criteria), MCTD initial and follow-up evaluations, MCTD treatment. Early diagnosis, epidemiological data, assessment of burden of disease and QOL aspects are among the unmet needs identified by patients.
Original languageEnglish
JournalRMD Open
Publication statusPublished - Oct 1 2018


  • clinical practice guidelines
  • ERN reconnet
  • european reference networks
  • mixed connective tissue disease
  • unmet needs


Dive into the research topics of 'Mixed connective tissue disease: State of the art on clinical practice guidelines'. Together they form a unique fingerprint.

Cite this